Close Menu
With their impending merger two weeks away, Thermo Electron and Fisher Scientific this week reported strong third-quarter revenue growth, though Thermo’s profits slid 15 percent while Fisher’s surged 62 percent.
 
For the quarter ended Sept. 30, Thermo said revenues grew 7 percent to $725 million, compared to $679 million a year ago. Net income dropped 15.4 percent to $49 million from $58 million a year ago, which included a $17 million gain on disposal of discontinued operations.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.